[1]Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time[J]. Lancet Infect Dis, 2020, 20: 533-534. [2]Staffolani S, Iencinella V, Cimatti M, et al. Long COVID-19 syndrome as a fourth phase of SARS-CoV-2 infection[J]. Infez Med, 2022, 30: 22-29. [3]Sriwastava S, Tandon M, Podury S, et al. COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-CoV2[J]. J Neurol, 2021, 268: 4448-4478. [4]Li Y, Ma ML, Lei Q, et al. Linear epitope landscape of the SARS-CoV-2 spike protein constructed from 1,051 COVID-19 patients[J]. Cell Rep, 2021, 34: 108915.doi:10.1016/j.celrep.2021.108915. [5]Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19[J]. Nature, 2021, 595: 283-288. [6]Ni S, Li C, Xu N, et al. Follistatin-like protein 1 induction of matrix metalloproteinase 1, 3 and 13 gene expression in rheumatoid arthritis synoviocytes requires MAPK, JAK/STAT3 and NF-kappaB pathways[J]. J Cell Physiol, 2018, 234: 454-463. [7]Karlsson M, Zhang C, Méar L, et al. A single-cell type transcriptomics map of human tissues[J]. Sci Adv, 2021, 7: eabh2169.doi:10.1126/sciadv.abh2169. [8]Shimizu F, Takeshita Y, Sano Y, et al. GRP78 anti-bodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndr-ome[J]. Brain, 2019,142:2253-2264. [9]Fotuhi M, Mian A, Meysami S, et al. Neurobiology of COVID-19[J]. J Alzheimers Dis, 2020,76:3-19. [10]Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases[J]. Front Immunol, 2021,11:617089.doi:10.3389/fimmu.2020.617089. |